FDA warns of unanswered safety questions for off-label testosterone use in menopause
At an FDA public workshop, officials said testosterone therapy for menopausal women is not FDA-approved and long-term safety data remain lacking.
The Food and Drug Administration held a public workshop on Thursday to discuss the growing off-label use of testosterone among menopausal women. While testosterone is the most abundant sex hormone in premenopausal women, its levels decline with age and low concentrations have been linked to reduced bone density, muscle mass, cognition, mood, sexual function and energy.
Because no testosterone formulation is approved for women in the United States, clinicians prescribe lower doses of products intended for men. Dr. Christina Chang, director of the FDA’s division of urology, obstetrics and gynecology, said, "There are no FDA-approved uses for testosterone therapy for menopausal women," and noted the agency’s awareness of increasing off-label prescriptions.
Current evidence for testosterone therapy in women focuses mainly on hypoactive sexual desire disorder, yet many women seek the hormone for broader concerns such as energy and mood, which are not recognized indications under existing guidelines. Measuring testosterone in women is also challenging due to low concentrations and the lack of a diagnostic blood-test threshold.
The discussion came as hormone replacement therapy prescriptions for women aged 50 to 65 have risen sharply, and the FDA recently removed black-box warnings from both HRT and testosterone products. Dr. Chang added, "To best serve American women we need high-quality data and we are looking forward to working with manufacturers to obtain that data."